jag009
★★★

NJ,
2013-08-14 01:30
(4691 d 03:14 ago)

Posting: # 11272
Views: 4,101
 

 Question about Treatment Effect [General Sta­tis­tics]

Hi all,

Question. From a 3-way (T1 vs T2 vs R) study, for Cmax:
  1. A is BE to R for Cmax (Ratio ~100%; 90%CI ~94-110%; pooled CV 27%)
  2. B is not BE to R (Ratio ~121%; 90%CI ~112-131; pooled CV 27%)
  3. A significant treatment effect was observed from the PROC GLM model output.
Obviously the significant treatment effect was caused by B-R, but how do you defend it?

Thanks
John
Helmut
★★★
avatar
Homepage
Vienna, Austria,
2013-08-14 02:53
(4691 d 01:51 ago)

@ jag009
Posting: # 11273
Views: 3,294
 

 significant ≠ relevant

Hi John,

❝ 3. A significant treatment effect was observed from the PROC GLM model output.

❝ Obviously the significant treatment effect was caused by B-R, but how do you defend it?

  1. Nothing to defend. A significant treatment effect is irrelevant in BE. Furthermore, from your data it is clear that it is caused by T2 in the analysis of the complete data set. Since the 90% CI of T1/R included 100% this treatment was not significantly different from R (only T2: the CI did not contain 100%).
  2. Drop Mr Schuirmann an [image] and ask for his 2004 presentation. Maybe it gives you an idea which kind of evaluation FDA prefers (complete model or dropping T2 in your case)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes
UA Flag
Activity
 Admin contact
23,654 posts in 4,992 threads, 1,571 registered users;
162 visitors (0 registered, 162 guests [including 16 identified bots]).
Forum time: 04:45 CEST (Europe/Vienna)

“Data! Data! Data!” he cried impatiently.
“I can’t make bricks without clay!”    Arthur Conan Doyle

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5